March 2, 2017 / 9:59 PM / 9 months ago

BRIEF-Regulus reports Q4 loss per share $0.38

March 2 (Reuters) - Regulus Therapeutics Inc:

* Regulus reports fourth quarter 2016 financial results and pipeline update

* Q4 loss per share $0.38

* Q4 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S

* Qtrly revenue was less than $0.1 million, compared to $10.9 million

* Q4 revenue view $917430.00 -- Thomson Reuters I/B/E/S

* Has modified PHASE II rg-012 clinical development program in patients with alport syndrome

* Regulus Therapeutics - Phase II Rg-012 program will include hera study, a 48-week study in 30 patients with rapid renal function decline

* Regulus Therapeutics - hera study objective is to evaluate safety, efficacy of RG-012 for treating renal function decline in patients with alport syndrome Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below